NL-OMON48017已完成2 期
A phase II, multicenter, randomized, two-arm study of capmatinib (INC280, an oral MET inhibitor) and spartalizumab (PDR001, a PD-1 inhibitor) combination therapy versus docetaxel in pretreated adult patient with EGFR wild-type, ALK rearrangement negative locally advanced/metastatic non-small cell lung cancer. - CINC280D2201
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 4
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Histologically confirmed locally advanced/metastatic (stage IIIB/IV) per
- •AJCC/IASLC v.8) NCSCL
- •* EGFR wild-type, ALK rearrangement negative, NSCLC
- •* Subject has demonstrated progression following one prior platinum doublet and
- •one prior PD-(L)1 checkpoint inhibitor (either alone or in combination, the most
- •recent treatment regimen must have contained a PD-(L)1 checkpoint inhibitor)
- •* Subjects must be candidates for single agent docetaxel
- •* Subjects must have at least one lesion evaluable by RECIST 1.1
排除标准
- •* Prior treatment with a MET inhibitor or HGF (Hepatocyte growth factor)
- •* Any untreated central nervous system (CNS) lesion
- •* Use of any live vaccines against infectious diseases within 12 weeks of
- •of study treatment
研究者
相似试验
进行中（未招募）
1 期
Study of safety and efficacy of INC280 in combination with PDR001, compared to chemotherapy, in advanced/ metastatic non-small cell lung cancer patients with no EGFR mutations or ALK rearrangements.EUCTR2018-001420-19-BGovartis Pharma AG18
进行中（未招募）
1 期
Study of safety and efficacy of INC280 in combination with PDR001, compared to chemotherapy, in advanced/ metastatic non-small cell lung cancer patients with no EGFR mutations or ALK rearrangements.on-small cell lung cancerMedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001420-19-NLovartis Pharma AG105
进行中（未招募）
1 期
Study of safety and efficacy of INC280 in combination with PDR001, compared to chemotherapy, in advanced/ metastatic non-small cell lung cancer patients with no EGFR mutations or ALK rearrangements.EUCTR2018-001420-19-ITOVARTIS PHARMA AG18
进行中（未招募）
1 期
Study of safety and efficacy of INC280 in combination with PDR001, compared to chemotherapy, in advanced/ metastatic non-small cell lung cancer patients with no EGFR mutations or ALK rearrangements.EUCTR2018-001420-19-ESovartis Farmacéutica, S.A18
进行中（未招募）
1 期
Study of safety and efficacy of INC280 in combination with PDR001, compared to chemotherapy, in advanced/ metastatic non-small cell lung cancer patients with no EGFR mutations or ALK rearrangements.on-small cell lung cancerMedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-001420-19-FRovartis Pharma AG105